Alkermes Plc · NASDAQ:ALKS

Alkermes — Q3 2026 Earnings Presentation

16 slides from Alkermes's earnings presentation, Nov 3, 2026

  1. Slide 1: Third Quarter 2026 Financial Results & Business Update

    Third Quarter 2026 Financial Results & Business Update November 3, 2026 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkerm

  3. Slide 3: Q3 2026 Financial and Operational Performance

    Q3 2026 Financial and Operational Performance

  4. Slide 4: Q3 2026 Financial Results Summary

    In millions Q3 2026 Financial Results Summary Total Revenue In millions GAAP Net Income GAAP Earnings Per Share Diluted 2026 results reflect the acquisition of Avadel in February 2026.

  5. Slide 5: Q3 2026 Profitability

    In millions Q3 2026 Profitability GAAP Net Income In millions Adjusted EBITDA* EBITDA* In millions EBITDA represents earnings before interest, tax, depreciation and amortization. Adjusted EBITDA excludes share‐based compensation expense and non‐recurring gains or losses in addition to the components

  6. Slide 6: Q3 2026 Revenue Summary

    Q3 2026 Revenue Summary In millions Q3’26 Q3’25 Total Proprietary Net Sales $417.3 $317.4 VIVITROL® $127.6 $121.1 ARISTADA®* $103.9 $98.1 LYBALVI® $95.9 $98.2 LUMRYZ® $89.9 -- Manufacturing & Royalty Revenue $62.9 $76.8 Total Revenue $480.1 $394.2 Amounts in the table may not sum due to rounding. *I

  7. Slide 7: Alkermes: 2026 Financial Expectations

    Alkermes: 2026 Financial Expectations a The acquisition of Avadel closed on Feb. 12, 2026. Expected net sales of LUMRYZ represents the period of Feb. 12, 2026 – Dec. 31, 2026. Avadel recorded net sales of LUMRYZ of approx. $33 million between Jan. 1, 2026 and Feb. 11, 2026. b In connection with the

  8. Slide 8: Q3 2026 Commercial Review

    Q3 2026 Commercial Review

  9. Slide 9: VIVITROL Performance and Expectations

    VIVITROL® Performance and Expectations *These expectations were initially provided by the Company on Feb. 25, 2026, are reiterated by the Company on Nov. 3, 2026 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q3’26 VIV

  10. Slide 10: ARISTADA Performance and Expectations

    ARISTADA® Performance and Expectations Q3’26 ARISTADA net sales were $103.9M Outlook: FY’26 net sales expected to range from $365M – $385M†* *Inclusive of ARISTADA INITIO® †These expectations were initially provided by the Company on Feb. 25, 2026, are reiterated by the Company on Nov. 3, 2026 and a

  11. Slide 11: LYBALVI Performance and Expectations

    LYBALVI® Performance and Expectations *These expectations were initially provided by the Company on Feb. 25, 2026, are reiterated by the Company on Nov. 3, 2026 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. **These ex

  12. Slide 12: LUMRYZ Performance and Expectations

    LUMRYZ® Performance and Expectations *These expectations were initially provided by the Company on Feb. 25, 2026, are reiterated by the Company on Nov. 3, 2026 and are effective only as of such date. The Company expressly disclaims any obligation to update or reaffirm these expectations. Q3’26 LUMRY

  13. Slide 13: Appendix

    Appendix

  14. Slide 14: Financial Results GAAP to Non-GAAP Reconciliation

    Appendix: Financial Results GAAP to Non-GAAP Reconciliation (In millions) Three Months Ended September 30, 2026 Three Months Ended September 30, 2025 Net Income — GAAP $ 16.3 $ 82.8 Adjustments: Interest income (6.5) (11.9) Interest expense 27.6 -- Income tax (benefit) provision (1.6) 18.0 Depreciat

  15. Slide 15: Financial Expectations GAAP to Non-GAAP Reconciliation

    Appendix: Financial Expectations GAAP to Non-GAAP Reconciliation Projected GAAP and non-GAAP measures in the table above reflect the mid-points within the Company’s financial expectations ranges. (In millions) Year Ended December 31, 2023 Year Ending December 31, 2026 Projected Net Loss — GAAP $ (10

  16. Slide 16: www.alkermes.com

    www.alkermes.com © 2026 Alkermes. All rights reserved.

Alkermes — Q3 2026 Earnings Presentation on 6ix